4.7 Review

Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy

Journal

MOLECULAR CANCER
Volume 19, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12943-020-1141-9

Keywords

Circulating tumor cells (CTCs); Isolation technologies; Prognosis; Immunotherapy; Immune mechanisms

Funding

  1. National Natural Science Foundation of China [30900650, 81372501, 81572260, 81172232, 31430030]
  2. Guangdong Natural Science Foundation [2011B031800025, S2012010008378, S2012010008270, S2013010015327, 2013B021800126, 20090171120070, 9451008901002146, 2014A030313052, 2014 J4100132, 2015A020214010, 2016A020215055, 20180506, 2013B021800259]
  3. Science and Technology Foundation of Shenzhen [JCYJ20170412155231633, 20180225112449943, JCYJ20180305164128430]

Ask authors/readers for more resources

Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available